Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

Launched by CENTRE HENRI BECQUEREL · Mar 14, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at ways to predict how well patients with triple-negative breast cancer will respond to a combination of chemotherapy and immunotherapy before they start treatment. Researchers want to find the best imaging techniques, such as scans, that can show if there are still tumor cells present after treatment. They are also interested in identifying certain blood markers that may help determine which patients are likely to benefit most from the treatment or who might experience more side effects, especially from immunotherapy.

To participate in this trial, women aged 18 to 75 who have been diagnosed with triple-negative breast cancer and are recommended for this type of treatment may be eligible. However, there are some important criteria to consider, such as not being pregnant, not having certain health conditions, and not having previous treatments that could interfere with the study. Participants will undergo imaging and blood tests as part of the study, and they will receive careful monitoring throughout the process. This research aims to make treatments more personalized, ensuring that patients receive the most effective care tailored to their individual needs.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Signed informed consent
• • Patient with histologically proven TNBC
• • Indication for neo-adjuvant chemo-immunotherapy treatment
• • Age between 18 and 75
• • Affiliated or beneficiary of a social protection scheme
• Exclusion Criteria:
• • Pregnant or breast-feeding women
• • Contraindication to immunotherapy
• • Inflammatory breast cancer (T4d)
• • Metastatic patients
• • Allergies to iodine or gadolinium
• • Patient with an augmentation prosthesis (for angiography/mammography)
• • Claustrophobic patients
• • Renal contraindication to contrast products according to SFR-CIRTACI
• • Ferromagnetic material
• • Uncontrolled diabetes (blood glucose \>10 mmol/L)
• • Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).
• • Patient under guardianship, curatorship or safeguard of justice